Literature DB >> 10381809

Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors.

S Ekins1, G Bravi, S Binkley, J S Gillespie, B J Ring, J H Wikel, S A Wrighton.   

Abstract

The program Catalyst was used to build three-dimensional quantitative structure activity relationship (3D-QSAR) pharmacophore models of the structural features common to competitive-type inhibitors of cytochrome P-450 (CYP) 3A4. These were compared with 3D- and four-dimensional (4D)-QSAR partial least-squares (PLS) models built using molecular surface-weighted holistic invariant molecular (MS-WHIM) descriptors for size and shape of the inhibitor. The Catalyst pharmacophore model generated from multiple conformers of competitive inhibitors of CYP3A4-mediated midazolam 1'-hydroxylation (n = 14) yielded a high correlation of observed and predicted Ki values of r = 0.91. Similarly, PLS MS-WHIM was used to produce 3D- and 4D-QSARs for this data set and produced models that were statistically predictable after cross-validation. Two additional Catalyst pharmacophores were constructed from literature Ki values (n = 32) derived from the inhibition of CYP3A-mediated cyclosporin A metabolism and IC50 data (n = 22) from the inhibition of CYP3A4-mediated quinine 3-hydroxylation. These Catalyst pharmacophores illustrated correlations of observed and predicted inhibition for CYP3A4 of r = 0.77 and 0.92, respectively. The corresponding 4D-QSARs generated by PLS MS-WHIM for these data sets were of comparable quality as judged by cross-validation. Both Ki pharmacophores generated with Catalyst were also validated by predicting the Ki(apparent) values of a test set of eight CYP3A4 inhibitors not included in either model. In seven of eight cases, the residuals of the predicted Ki(apparent) values were within 1 log unit of the observed values. The 3D- and 4D-QSAR models produced in this study suggest the utility of future in silico prediction of CYP3A4-mediated drug-drug interactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10381809

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

1.  Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes.

Authors:  Zongling Xia; Mingli Wang; Sulan Zou; Rong Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 2.441

Review 2.  A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta.

Authors:  Sean Ekins; Leonid Mirny; Erin G Schuetz
Journal:  Pharm Res       Date:  2002-12       Impact factor: 4.200

3.  A support vector machine approach to classify human cytochrome P450 3A4 inhibitors.

Authors:  Jan M Kriegl; Thomas Arnhold; Bernd Beck; Thomas Fox
Journal:  J Comput Aided Mol Des       Date:  2005-03       Impact factor: 3.686

4.  Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst.

Authors:  Madhu Chopra; Ruby Gupta; Swati Gupta; Daman Saluja
Journal:  J Mol Model       Date:  2008-07-30       Impact factor: 1.810

Review 5.  Modeling kinetics of subcellular disposition of chemicals.

Authors:  Stefan Balaz
Journal:  Chem Rev       Date:  2009-05       Impact factor: 60.622

6.  Towards a new age of virtual ADME/TOX and multidimensional drug discovery.

Authors:  Sean Ekins; Bruno Boulanger; Peter W Swaan; Maggie A Z Hupcey
Journal:  J Comput Aided Mol Des       Date:  2002 May-Jun       Impact factor: 3.686

Review 7.  Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  Development of a generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery.

Authors:  R J Riley; A J Parker; S Trigg; C N Manners
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

9.  Trainable structure-activity relationship model for virtual screening of CYP3A4 inhibition.

Authors:  Remigijus Didziapetris; Justas Dapkunas; Andrius Sazonovas; Pranas Japertas
Journal:  J Comput Aided Mol Des       Date:  2010-09-01       Impact factor: 3.686

10.  QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method.

Authors:  Suchada Wanchana; Fumiyoshi Yamashita; Mitsuru Hashida
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.